Followers | 788 |
Posts | 118590 |
Boards Moderated | 15 |
Alias Born | 09/05/2002 |

Wednesday, July 27, 2022 7:44:52 AM
https://news.bms.com/news/corporate-financial/2022/Bristol-Myers-Squibb-Reports-Second-Quarter-Financial-Results-for-2022/default.aspx
2022 non-GAAP EPS guidance remains $7.44-7.74.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent BMY News
- Amazon Unveils Innovative Services, Okta Discloses Data Breach, Textron Plans 2% Global Workforce Reduction, and More • IH Market News • 11/29/2023 11:18:11 AM
- FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells • Dow Jones News • 11/28/2023 08:08:00 PM
- Bristol Myers Squibb to Take Stake in Avidity Biosciences, Expand Partnership • Dow Jones News • 11/28/2023 12:21:00 PM
- Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology • PR Newswire (US) • 11/28/2023 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/24/2023 07:38:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 12:01:13 AM
- Trending: Bristol Myers Squibb's Blood Cancer Treatment Approval Delayed by FDA • Dow Jones News • 11/20/2023 07:31:00 PM
- Bristol-Myers Squibb on Track for Lowest Close Since March 2020 -- Data Talk • Dow Jones News • 11/20/2023 03:58:00 PM
- 2seventy Bio Shares Fall Premarket on Abecma Expansion Delay • Dow Jones News • 11/20/2023 01:30:00 PM
- FDA Advisory Panel to Meet on Earlier Use of Abecma From Bristol, 2seventy • Dow Jones News • 11/20/2023 12:56:00 PM
- Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma • Business Wire • 11/20/2023 11:59:00 AM
- U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) • Business Wire • 11/16/2023 12:20:00 AM
- Bristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference • Business Wire • 11/09/2023 09:18:00 PM
- Bristol Myers Gets FDA Priority Review of Expanded Breyanzi Label • Dow Jones News • 11/09/2023 04:08:00 PM
- U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) • Business Wire • 11/09/2023 03:14:00 PM
- Orphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That Time • AllPennyStocks.com • 11/07/2023 09:01:00 PM
- Tuesday’s Wall Street Highlights: WeWork, UBS, Sanofi, Alteryx, Intel, and more. • IH Market News • 11/07/2023 12:10:06 PM
- Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023 • Business Wire • 11/06/2023 11:59:00 AM
- Bristol-Myers Squibb On Track for Largest Percent Increase Since June 2022 -- Data Talk • Dow Jones News • 11/03/2023 05:55:00 PM
- Bristol Myers Squibb’s First Disclosures and New Data at ASH 2023 Highlight Company’s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology • Business Wire • 11/02/2023 03:34:00 PM
- Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference • Business Wire • 11/02/2023 10:59:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/01/2023 08:16:39 PM
- Bristol Myers Names Incoming CEO Boerner as Next Chairman • Dow Jones News • 10/31/2023 11:09:00 PM
- Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024 • Business Wire • 10/31/2023 10:25:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 10/31/2023 08:30:59 PM
CGrowth Capital Inc. Sets Stage for Exciting 2024 with Savage Barbell Apparel Expansion • CGRA • Nov 28, 2023 11:15 AM
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing • IMMX • Nov 28, 2023 10:48 AM
Swifty Global Secures GLI Certification for New Cutting-Edge B2B Gaming Platform • DRCR • Nov 28, 2023 9:15 AM
Nate's Food Co. Successfully Obtains GACC Registration in China, Paving the Way for Contract Execution on Commodities • NHMD • Nov 28, 2023 8:00 AM
Mass Megawatts Announces LOWEST PRICE GUARANTEE on Solar Project Sales and Further Cost Reductions Using our Patent Pending Technologies • MMMW • Nov 28, 2023 8:00 AM
Branded Legacy Commences Buyback of 1,000,000 Preferred Class D Shares • BLEG • Nov 28, 2023 7:23 AM